Tofacitinib for Prurigo Nodularis: A Case Report
Changlan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology, Hospital of Chengdu University of Tr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-03-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/tofacitinib-for-prurigo-nodularis-a-case-report-peer-reviewed-fulltext-article-CCID |
| _version_ | 1818317568264372224 |
|---|---|
| author | Peng C Li C Zhou Y Wang Q Xie P Li T Hao P |
| author_facet | Peng C Li C Zhou Y Wang Q Xie P Li T Hao P |
| author_sort | Peng C |
| collection | DOAJ |
| description | Changlan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tianhao Li; Pingsheng Hao, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, People’s Republic of China, Tel +86-13880986337 ; +86-13881965024, Fax +86-28-87732407, Email litianhao_doctor@163.com; hpswl@126.comPurpose: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.Patients and Methods: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.Results: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.Conclusion: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.Keywords: prurigo nodularis, JAK inhibitors, tofacitinib |
| first_indexed | 2024-12-13T09:39:23Z |
| format | Article |
| id | doaj.art-7780a5c880124ccaa0f566cdcda9861c |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-12-13T09:39:23Z |
| publishDate | 2022-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-7780a5c880124ccaa0f566cdcda9861c2022-12-21T23:52:13ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152022-03-01Volume 1550350673832Tofacitinib for Prurigo Nodularis: A Case ReportPeng CLi CZhou YWang QXie PLi THao PChanglan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tianhao Li; Pingsheng Hao, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, People’s Republic of China, Tel +86-13880986337 ; +86-13881965024, Fax +86-28-87732407, Email litianhao_doctor@163.com; hpswl@126.comPurpose: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.Patients and Methods: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.Results: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.Conclusion: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.Keywords: prurigo nodularis, JAK inhibitors, tofacitinibhttps://www.dovepress.com/tofacitinib-for-prurigo-nodularis-a-case-report-peer-reviewed-fulltext-article-CCIDprurigo nodularisjak inhibitorstofacitinib. |
| spellingShingle | Peng C Li C Zhou Y Wang Q Xie P Li T Hao P Tofacitinib for Prurigo Nodularis: A Case Report Clinical, Cosmetic and Investigational Dermatology prurigo nodularis jak inhibitors tofacitinib. |
| title | Tofacitinib for Prurigo Nodularis: A Case Report |
| title_full | Tofacitinib for Prurigo Nodularis: A Case Report |
| title_fullStr | Tofacitinib for Prurigo Nodularis: A Case Report |
| title_full_unstemmed | Tofacitinib for Prurigo Nodularis: A Case Report |
| title_short | Tofacitinib for Prurigo Nodularis: A Case Report |
| title_sort | tofacitinib for prurigo nodularis a case report |
| topic | prurigo nodularis jak inhibitors tofacitinib. |
| url | https://www.dovepress.com/tofacitinib-for-prurigo-nodularis-a-case-report-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT pengc tofacitinibforprurigonodularisacasereport AT lic tofacitinibforprurigonodularisacasereport AT zhouy tofacitinibforprurigonodularisacasereport AT wangq tofacitinibforprurigonodularisacasereport AT xiep tofacitinibforprurigonodularisacasereport AT lit tofacitinibforprurigonodularisacasereport AT haop tofacitinibforprurigonodularisacasereport |